CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).
  
  OVERVIEW OF ACTIVITY
  MM is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancers and carries with it one of the worst ratios of death to new cases. Although MM will represent only 1.8% of all new cancer cases diagnosed in the United States in 2020, practicing clinicians would be hard pressed to identify an area of oncology in which the research database — and available treatments — has evolved more rapidly over the past decade. In addition, novel agents, including proteasome inhibitors, immunomodulatory agents and Bruton tyrosine kinase inhibitors, have significantly altered the natural history of MM.
  
  To bridge the gap between research and patient care, this program produced in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development features a presentation by and one-on-one interview with a leading hematology-oncology investigator exploring clinical research, published data sets and ongoing trials in addition to a review of the results of a comprehensive web-based survey consisting of case-based and practical management questions regarding the optimal clinical care of patients with MM. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Discuss research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients eligible or ineligible for stem cell transplant, and effectively identify if and how this strategy should be integrated into clinical management.
  • Review published research data validating the use of minimal residual disease (MRD) status to assess response to active therapy and to identify disease recurrence, and use this information to determine the potential role of MRD assays in the protocol and nonresearch clinical care of patients with MM.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic strategies in the nonresearch care of patients with relapsed/refractory MM.
  • Recognize the recent FDA approval of belantamab mafodotin for relapsed/refractory MM, and identify patients for whom this treatment may be appropriate.
  • Explore available data documenting the activity of chimeric antigen receptor T-cell therapy and bispecific T-cell engagers designed to target B-cell maturation antigen, and use this knowledge to identify patients with MM who may be appropriate to receive these therapeutic approaches as part of clinical trials.

  COMPETENCIES TO BE ADDRESSED
  Patient Care and Procedural Skills and Medical Knowledge.
  
  CONTACT INFORMATION
  If you have questions regarding credit, please contact cpdsupport@usf.edu.
  
  

  ACCREDITATION STATEMENT
  USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Anne and Bernard Gray Family Chair in Cancer
  Chief Medical Officer
  Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.
  
  Krina K Patel, MD, MSc
  Associate Professor
  Center Medical Director
  Department of Lymphoma/Myeloma
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Precision BioSciences, Takeda Oncology; Consulting Agreement: Pfizer Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Takeda Oncology.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.
  
  Release date: April 2021
  Expiration date: April 2022